MAVENCLAD (cladribine tablets) is available through public drug plans for the majority of eligible Canadians with Relapsing-Remitting Multiple Sclerosis
MISSISSAUGA, ON, Oct. 27, 2020 /CNW/ - EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce that eligible patients have access to PrMAVENCLAD® (cladribine tablets) through seven provincial public drug plans including the Régie de l'assurance maladie du Québec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program. This is an important step to ensure broader, equitable and timely access to MAVENCLAD for eligible patients across Canada.
Eligible patients in Alberta, Manitoba, New Brunswick, Nova Scotia, Ontario, Quebec and Saskatchewan living with relapsing-remitting multiple sclerosis (RRMS) can now access MAVENCLAD through their public drug programs. MAVENCLAD is also currently reimbursed by the Non-Insured Health Benefits (NIHB) Program, Veteran's Affairs Canada (VAC) and most private drug insurance plans across the country.
"Patients living with MS can face significant daily and long-term challenges on their journey. Access to new and innovative medications to ease that burden should not pose an obstacle to MS patients," said Dr. Alexandre Prat, Neurologist and Researcher at CRCHUM, Canada Research Chair in Multiple Sclerosis Professor of Neuroscience and Associate Vice-Dean for Clinical Research, Faculty of Medicine, University of Montreal. "The addition of MAVENCLAD, a short course oral treatment, to provincial benefit plans provides a welcomed option for patients and physicians."
MAVENCLAD is available through the majority of the public drug plans following the positive reimbursement recommendations from the Institut national d'excellence en santé et en services sociaux (INESSS) in February 2020 and the CADTH Canadian Drug Expert Committee (CDEC) in October 2018. Negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) were completed in late 2019.
"On average, 11 Canadians are diagnosed with MS every day. Ensuring Canadians have access to all Health Canada approved treatments for MS is vital to help manage their disease and live well," said Pamela Valentine, President and CEO of the MS Society of Canada.
Canada has one of the highest rates of MS in the world, with an estimated 1 in 385 people living with the disease.i EMD Serono, Canada, is committed to supporting those living with the disease and strives to lead innovation in the field of MS.
"We are delighted that the majority of eligible patients with RRMS can access MAVENCLAD through public drug plans," said Robert Woolstencroft, Head of Patient Access & Government Affairs of EMD Serono, Canada. "We continue to work with other participating jurisdictions so eligible patients with RRMS across Canada have timely and equitable access to MAVENCLAD through their public drug plans."
MAVENCLAD has been approved in over 80 countries including the United States, European Union (EU), Australia and Switzerland, for various relapsing MS indications.
The clinical development program of MAVENCLAD in MS comprises more than 12,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. These clinical trials include the Phase III CLARITY, CLARITY extension and ORACLE MS trials, the Phase II ONWARD trial and the PREMIERE Long-term Safety Registry.
About Multiple Sclerosis
About EMD Serono, Canada
About Merck KGaA, Darmstadt, Germany
The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
SOURCE EMD Serono, Canada